Targeting Latently Infected Cells Without Reactivation (R01)
Grant Amount: NIAID intends to commit $2.7 million in FY2015 to fund 4-7 awards.
The purpose of this Funding Opportunity Announcement (FOA) is to solicit innovative research that advances the understanding of mechanisms or approaches that could be harnessed to selectively eliminate HIV-1 latently-infected cells without depending on viral reactivation. The ultimate goal is to inform the design of future therapeutic approaches that could be used to eradicate the latent reservoir that persists in the context of optimally suppressive highly active antiretroviral therapy (HAART), thereby affecting a permanent cure for HIV infection. Cross-disciplinary collaborations enabling technology-driven strategies are strongly encouraged.
As opposed to the creation of more effective strategies to reactivate latent provirus or to develop strategies to eliminate cells expressing viral proteins, the purpose of this Funding Opportunity Announcement (FOA) is to stimulate highly innovative research to advance the understanding of mechanisms or approaches that could be harnessed to selectively eliminate HIV-1 latently-infected cells without depending on viral reactivation or viral protein expression. The ultimate goal is to inform the design of future therapeutic approaches to cure HIV infection that do not require reversing latency. In order to move toward this goal, this FOA is focused on the following three objectives:
(1) Identification of biomarkers/molecular signatures of latently-infected cells that could be used to selectively target and kill cells harboring latent HIV-1 DNA; (2) Novel approaches to selectively eliminate latently-infected cells that do not require reactivation or HIV gene expression; (3) Approaches to permanently inactivate integrated HIV provirus.
Due to the inherent complexity of the latent reservoir, applications that leverage cross-disciplinary collaborations to apply cutting-edge technologies are especially encouraged.
For the purposes of this FOA, a latent viral reservoir is defined as an infected cell population that allows for the indefinite persistence of replication-competent HIV-1 in patients on optimal HAART regimens.
National Institute of Allergy and Infectious Diseases Division of AIDS
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Number of Awards Given
4 to 7 awards
Award Amount Notes
NIAID intends to commit $2.7 million in FY2015 to fund 4-7 awards.
Antiretroviral Drugs HIV/AIDS Prevention Medical Treatments and Therapies Research Programs
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.